Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Prescribing Information DownloadPatient Websites HCP Websites menu

Visit Patient Site

View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Patient Support

SucraidASSIST™ Program

The SucraidASSIST™ program is provided by QOL Medical, LLC and offers patient support services for patients diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID), their caregivers, and healthcare providers. The SucraidASSIST™ program is the source for information regarding drug and disease education, diet resources, and daily living for patients taking Sucraid®.

In This Section

SucraidASSIST™ Patient Support Program

SucraidASSIST™ (“Access and Support Services in Sucraid® Therapy”) is a comprehensive program of support, education, and financial assistance services for eligible U.S. patients with Congenital Sucrase-Isomaltase Deficiency (CSID). SucraidASSIST™ is staffed by dedicated Sucraid® specialists who are available to answer all Sucraid®-related questions.

The first point of contact in SucraidASSIST™ is through our patient care coordinators, who provide the following services:

  • Serve as the single point-of-contact for all SucraidASSIST™ patient support services
  • Assess and triage referred patients to the appropriate SucraidASSIST™ professionals
  • Obtain authorization and consent for referral of patients to optional support services
  • Follow-up periodically with current Sucraid® patients to assess their satisfaction with therapy
  • Contact patients who discontinue therapy for rescue attempts/referral to services as needed

What Does SucraidASSIST™ Do?

Dedicated Sucraid® Specialists
  • Provide support and education
  • Primary point of contact
Financial Assistance for Sucraid® Patients
  • Copay assistance may be available
  • Deductible and premium support
Insurance Coverage Assessment
  • Prior authorization assistance
  • Most plans cover Sucraid®
Medicaid/Medicare Appeal Support
  • Assistance with an appeal of Medicaid and Medicare plans if coverage for Sucraid® is initially denied
Nutritional Support
  • Resources for diet management

To Enroll in the SucraidASSIST™ Program

Electronic Enrollment

Click the link below to complete the form and electronically enroll in the SucraidASSIST™ program.

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.